SCHEMBL2334415

SCHEMBL2334415

CCN(CC)C(=O)c1cc(F)c(F)cc1Br

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.46
USP2 O75604 1/20 0.41
HSP90AA1 P07900 4/20 0.41
HSP90AB1 P08238 4/20 0.41
LMNA P02545 2/20 0.39
GFER P55789 1/20 0.39
TSHR P16473 1/20 0.38
COMT P21964 1/20 0.38
MLYCD O95822 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
ALDH1A1 P00352 3/20 0.37
RAB9A P51151 2/20 0.37
NPC1 O15118 1/20 0.37
TP53 P04637 1/20 0.37
MAPK1 P28482 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
RECQL P46063 1/20 0.37
KEAP1 Q14145 1/20 0.36
ALOX5AP P20292 1/20 0.36
FEN1 P39748 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25141574 0.79 HPGD (0.47) HPGDUSP2HSP90AA1HSP90AB1LMNA
SCHEMBL31330707 0.77 ERN1 (0.42) HPGDUSP2HSP90AA1HSP90AB1LMNA
SCHEMBL3341268 0.76 DGAT1 (0.54) HPGDUSP2HSP90AA1HSP90AB1LMNA
SCHEMBL31330786 0.76 HSP90AA1 (0.39) HPGDUSP2HSP90AA1HSP90AB1LMNA
SCHEMBL2336464 0.76 LCK (0.59) HPGDUSP2HSP90AA1HSP90AB1TSHR
SCHEMBL27850334 0.76 ALDH1A1 (0.41) HPGDHSP90AB1LMNATSHRALDH1A1
SCHEMBL7305124 0.74 HPGD (0.40) HPGDUSP2HSP90AA1HSP90AB1LMNA
SCHEMBL7294976 0.74 HPGD (0.40) HPGDHSP90AA1HSP90AB1LMNATSHR
SCHEMBL7421174 0.74 HPGD (0.40) HPGDHSP90AA1HSP90AB1LMNATSHR
SCHEMBL17877022 0.74 HPGD (0.53) HPGDUSP2HSP90AA1HSP90AB1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025011623-A1 CYANOQUINOLINE-TARGETING PROTEIN DEGRADATION MOLECULE, PREPARATION METHOD THEREFOR AND USE THEREOF 上海壹迪生物技术有限公司 2025-01-16 WO disclosed
EP-2356110-B1 QUINAZOLINAMIDE DERIVATIVES MERCK PATENT GMBH (DE) 2016-01-06 EP disclosed
US-8546565-B2 Quinazolinamide derivatives MERCK PATENT GESELLSCHAFT (DE) 2013-10-01 US disclosed
US-8546565-B2 Quinazolinamide derivatives MERCK PATENT GESELLSCHAFT (DE) 2013-10-01 US disclosed
US-8546565-B2 Quinazolinamide derivatives MERCK PATENT GESELLSCHAFT (DE) 2013-10-01 US disclosed
US-20110245225-A1 QUINAZOLINAMIDE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTING (DE) 2011-10-06 US disclosed
US-20110245225-A1 QUINAZOLINAMIDE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTING (DE) 2011-10-06 US disclosed
US-20110245225-A1 QUINAZOLINAMIDE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTING (DE) 2011-10-06 US disclosed
EP-2356110-A1 QUINAZOLINAMIDE DERIVATIVES Merck Patent GmbH (DE) 2011-08-17 EP disclosed
WO-2010066324-A1 QUINAZOLINAMIDE DERIVATIVES MERCK PATENT GMBH (DE) 2010-06-17 WO disclosed
WO-2010066324-A1 QUINAZOLINAMIDE DERIVATIVES MERCK PATENT GMBH (DE) 2010-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110245225-A1 QUINAZOLINAMIDE DERIVATIVES HSP90AB1, HSP90AA1, HSP90B1 HPGD 484/4885USP2 1873/4885HSP90AA1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.